MICA and MICB are expressed on the surface of stressed, virus infected and cancer cells； they bind to their common receptor NKG2D on immune effector cells such as natural killer (NK) cells and some T cells to signal immune responses, including cytotoxicity, towards cells expressing surface MICA or MICB. To evade this immune-surveillance, virus infected cells and cancer cells shed the extracellular domain of their MICA and MICB as soluble forms (sMICA and sMICB) which act as decoys by binding and down-regulating expression of NKG2D on the immune effector cells. Antibodies are provided that specifically bind the soluble forms of both MICA and MICB to inhibit their adverse effects, but do not bind cell- or membrane-bound MICA and MICB to preserve their beneficial immune effects.La présente invention concerne des agents de liaison, notamment des anticorps, qui se lient à MICA et/ou MICB； des compositions comprenant les agents de liaison； et l'utilisation des agents de liaison pour des diagnostics et des traitements de maladies caractérisées par des protéines MICA et/ou MICB élevées.
